Results 21 to 30 of about 6,944 (246)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential [PDF]

International Journal of Biological Sciences, 2021
Type 2 diabetes mellitus (T2DM) is closely associated with cardiovascular diseases (CVD), including atherosclerosis, hypertension and heart failure. Some anti-diabetic medications are linked with an increased risk of weight gain or hypoglycemia which may reduce the efficacy of the intended anti-hyperglycemic effects of these therapies.
Ma, X, Liu, Z, Ilyas, I, Little, PJ, Kamato, D, Sahebka, A, Chen, Z, Luo, S, Zheng, X, Weng, J, Xu, S   +10 more
openaire   +3 more sources

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study

Cardiovascular Diabetology, 2020
Background Current evidence about the cardiovascular safety of glucagon-like peptide-1 receptor agonist (GLP-1ra) possesses limited generalizability to real-world patients with type 2 diabetes (T2D) in usual practice.
Chun-Ting Yang, Chen-Yi Yang, Huang-Tz Ou, Shihchen Kuo   +3 more
doaj   +1 more source

Gut microbiota modulation in GLP-1RA and SGLT-2i therapy: clinical implications and mechanistic insights in type 2 diabetes [PDF]

Clin Kidney J
Mehmet Kanbay, Rama Al-Shiab, E Abu Shah, Laşin Özbek, Mustafa Güldan, Alberto Ortíz, Denis Fouque   +6 more
openalex   +2 more sources

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits

Military Medical Research, 2022
AbstractGlucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus (T2DM). Both anti-diabetic treatments function by playing key modulatory roles in the incretin system.
Michael Razavi, Ying-Ying Wei, Xiao-Quan Rao, Ji-Xin Zhong   +3 more
openaire   +3 more sources

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs

Cardiovascular Diabetology, 2022
Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose co-transporter-2 (SGLT-2) inhibitors reduce cardiorenal outcomes. We performed a network meta-analysis to compare the effect on cardiorenal outcomes among GLP-1 RAs, SGLT-2
Dario Giugliano, Miriam Longo, Simona Signoriello, Maria Ida Maiorino, Bruno Solerte, Paolo Chiodini, Katherine Esposito   +6 more
doaj   +1 more source

Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China

Frontiers in Endocrinology, 2022
BackgroundsRobust evidence have demonstrated the beneficial effect of Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in T2D patients with cardiovascular diseases and chronic kidney disease ...
Cao Li, Shanshan Guo, Jiping Huo, Yiming Gao, Yiming Gao, Yilong Yan, Yilong Yan, Zhigang Zhao   +7 more
doaj   +1 more source

GLP-1 RA Improves Diabetic Retinopathy by Protecting the Blood-Retinal Barrier through GLP-1R-ROCK-p-MLC Signaling Pathway

Journal of Diabetes Research, 2022
Background. GLP-1 receptor agonists (GLP-1RA) are common clinical agents that are clinically protective against diabetic complications, such as diabetic retinopathy (DR).
Liufeng Wei, Weiwei Mo, Shanshan Lan, Haiyan Yang, Zhenxing Huang, Xinghuan Liang, Li Li, Jing Xian, Xuemei Xie, Yingfen Qin, Faquan Lin, Zuojie Luo   +11 more
doaj   +1 more source

Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysisResearch in context

EClinicalMedicine, 2023
Summary: Background: Innovative GLP-1 receptor agonist (GLP-1RA)-based treatment strategies—such as tirzepatide, GLP-1RA plus basal insulin fixed-ratio combinations [FRC], GLP-1RA plus sodium glucose cotransporter-2 inhibitors [SGLT-2i] combinations ...
Irene Caruso, Ludovico Di Gioia, Sergio Di Molfetta, Angelo Cignarelli, Suetonia Cressida Palmer, Patrizia Natale, Giovanni F.M. Strippoli, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino   +10 more
doaj   +1 more source

Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies [PDF]

Diabetes Obes Metab
Reimar W. Thomsen, Aurélie Mailhac, Julie B. Løhde, Anton Pottegård   +3 more
openalex   +2 more sources

Semaglutide seems to be more effective the other GLP-1Ras [PDF]

Annals of Translational Medicine, 2017
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were introduced as treatment options for type 2 diabetes (T2DM) in 2005 (1). They have become popular because of their efficacy and durability in relation to glycaemic control, and their low risk of hypoglycaemia in combination with weight loss in most patients (2,3).
Holst, Jens Juul, Madsbad, Sten
openaire   +3 more sources